ArticleGeroScience2025
5-HT
Article in GeroScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Age-related differences in motor unit discharge rate modulation across contraction levels.GeroScience · 2026Article
- Motor Cortex Hyperexcitability Is Coupled to Neuromuscular Dysfunction in Aged Mice.Aging cell · 2026Article
- Neuromuscular junction failure in sarcopenia is linked to NaV1.4 loss and reversed by ClC-1 inhibition.The Journal of clinical investigation · 2026Article
- Weighted cart pull: A novel outcome measure for sustained motor function in mice.Experimental physiology · 2025Article
- Intrinsic Motoneuron Excitability Differentiates Sarcopenic, Nonsarcopenic and Athletic Ageing Phenotypes.Journal of cachexia, sarcopenia and muscle · 2025Article
- Loss of 5-HTFrontiers in neural circuits · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Sarcopenia, the pathological age-related loss of muscle mass and strength, contributes to physical decline, frailty, and diminished healthspan. The impact of sarcopenia is expected to rise as the aging population grows, and treatments remain limited. Therefore, novel approaches for enhancing physical function and strength in older adults are desperately needed. Recent evidence suggests that deficits in motor neuron excitability contribute significantly to age-related weakness. Accordingly, we hypothesized that enhancing motor neuron excitability could be a novel strategy for mitigating age-related declines in physical function and strength. To test this hypothesis, we targeted the 5-HT
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.